Herpetic Simplex keratitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Herpetic Simplex keratitis Market Outlook

Thelansis’s “Herpetic Simplex keratitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpetic Simplex keratitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Herpetic Simplex keratitis Overview

A herpetic simplex keratitis is a form of keratitis caused by recurrent herpes simplex virus (HSV) infection in the cornea. It begins with the infection of epithelial cells on the eye's surface and retrograde infection of nerves serving the cornea. Primary infection is characterized by swelling of the conjunctiva and eyelids (Blepharoconjunctivitis) and small white itchy lesions on the corneal surface. The severity of the lesions varies, ranging from minor epithelial damage (superficial punctate keratitis) to more severe consequences such as the formation of dendritic ulcers. Humans are commonly infected with HSV. It is estimated that one-third of the world's population is infected regularly. Keratitis caused by HSV is the leading cause of corneal blindness in developed countries. As a result, HSV infections are a significant and global public health issue. Herpes simplex virus (HSV) is a ubiquitous DNA virus that can infect virtually anywhere in the body, particularly when newborns are infected. However, in an individual with a standard immune system, the most common sites of infection are the mouth, genitalia, and eyes. In very young children and adults, the brain may also become infected in rare instances. HSV infections of the eye are the leading cause of infectious corneal blindness in developed countries. While most infections are unilateral, some percentage of affected individuals have bilateral ocular infections. Bilateral infections are seen primarily in immunocompromised patients. Infections can occur in anterior aposteyeye segments eye, but it most commonly infects the corneal epithelia.

• The incidence of Herpetic simplex keratitis ranges from 15 to 20 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: